TY - CHAP M1 - Book, Section TI - Genetic and Genomic Testing in the Newborn Period A1 - Gomella, Tricia Lacy A1 - Eyal, Fabien G. A1 - Bany-Mohammed, Fayez Y1 - 2020 N1 - T2 - Gomella's Neonatology: Management, Procedures, On-Call Problems, Diseases, and Drugs, 8e AB - Genetic testing is not a new concept in neonatology. Newborn metabolic screening is the largest utilization of universal genetic testing in medicine and has been used in neonatology since 1960. It was then that Dr. Robert Guthrie developed a blood test to screen infants for phenylketonuria. It is estimated that birth defects are detected in 3% to 6% of live births and that congenital malformations, deformations, and chromosomal abnormalities are the cause of approximately 20% of deaths before 1 year of age. Many genetic conditions present in the perinatal period. Understanding of the available technology and the ability to manage all the steps involved in genomic testing have become essential tools for nongenetic specialists, including neonatologists and pediatricians. The study of genetics and genomics overlaps in the DNA analysis of specific genes, with the majority of diseases having complex genetic signatures. Genomics is a relatively new field, arising with the completion of the Human Genome Project in 2003, which mapped over 3 billion nucleotides in the 23 human chromosomes. Genomic technology advances have had a major impact on the care of newborns, especially those who are critically ill. Consequently, genomic testing is used more frequently, and as a result, pediatric providers need to be knowledgeable about the wide variety of tools that are becoming available. Information in this chapter is applicable to the newborn screening and congenital abnormalities discussed in Chapters 16 and 93. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/04/18 UR - accesspediatrics.mhmedical.com/content.aspx?aid=1168356025 ER -